HDT Bio Corp v. Emcure Pharmaceuticals Ltd
This text of HDT Bio Corp v. Emcure Pharmaceuticals Ltd (HDT Bio Corp v. Emcure Pharmaceuticals Ltd) is published on Counsel Stack Legal Research, covering District Court, W.D. Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
1 2
3 4 5 6 7 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON 8 AT SEATTLE
9 10 HDT BIO CORP., CASE NO. C22-0334JLR 11 Plaintiff, ORDER v. 12 EMCURE PHARMACEUTICALS, 13 LTD., 14 Defendant. 15 I. INTRODUCTION 16 Before the court is Defendant Emcure Pharmaceuticals, Ltd.’s (“Emcure”) motion 17 for attorneys’ fees under RCW 4.28.185(5). (Mot. (Dkt. # 199); Reply (Dkt. # 224).) 18 Plaintiff HDT Bio Corp. (“HDT”) opposes the motion. (Resp. (Dkt. # 221).) The court 19 // 20 // 21 // 22 1 has considered the parties’ submissions, the relevant portions of the record, and the 2 governing law. Being fully advised,1 the court DENIES Emcure’s motion.
3 II. BACKGROUND 4 HDT filed this action for trade secret misappropriation under the federal Defend 5 Trade Secrets Act (“DTSA”), 18 U.S.C. § 1836, and Washington’s Uniform Trade 6 Secrets Act (“UTSA”), RCW 19.108.010 et seq. (Am. Compl. (Dkt. # 133) at 82-85.) 7 The parties litigated for 21 months and engaged in over a year of jurisdictional discovery 8 before the court granted Emcure’s motion to dismiss for lack of personal jurisdiction and
9 dismissed HDT’s claims without prejudice. (See generally 12/4/23 Order (Dkt. # 195).) 10 The court concluded that it lacked jurisdiction over Emcure, an Indian pharmaceutical 11 company, because Emcure’s ties to the United States were too “random, fortuitous, or 12 attenuated” for the court to exercise personal jurisdiction over it. (Id. at 14 (quoting 13 Walden v. Fiore, 571 U.S. 277, 286 (2014)).)
14 Emcure then filed the instant motion. (See generally Mot.) Emcure brings its 15 motion solely under RCW 4.28.185(5), seeking $3,246,758.81 in attorneys’ fees and 16 costs. (Id. at 1, 13.) 17 III. ANALYSIS 18 RCW 4.28.185(5) provides as follows:
19 In the event the defendant is personally served outside the state on causes of action enumerated in this section, and prevails in the action, there may be 20
21 1 Neither party requests oral argument (see Mot. at 1; Resp. at 1), and the court concludes that oral argument would not be helpful to its disposition of this motion, see Local 22 Rules W.D. Wash. LCR 7(b)(4). 1 taxed and allowed to the defendant as part of the costs of defending the action a reasonable amount to be fixed by the court as attorneys’ fees. 2 RCW 4.28.185(5). The statute “authorizes an award of attorney fees when a foreign 3 defendant prevails on jurisdictional grounds.” Scott Fetzer Co. v. Weeks, 786 P.2d 265, 4 266 (Wash. 1990). One of RCW 4.28.185(5)’s purposes is to deter plaintiffs from 5 “harass[ing] foreign defendants.” Id. at 272 n.6. “Whether to grant or deny a request for 6 attorneys fees under this provision is wholly within the discretion of the trial court.” 7 Amazon.com, Inc. v. Kalaydjian, No. C00-1740BJR, 2001 WL 1892190, at *1 (W.D. 8 Wash. Mar. 27, 2001) (citing Fluke Cap. & Mgmt. Servs. Co. v. Richmond, 724 P.2d 356, 9 363-64 (Wash. 1986)). 10 Importantly, any award under RCW 4.28.185(5) “is limited to the amount 11 necessary to compensate a foreign defendant for the added costs of litigating in 12 Washington.” W. Consultants, Inc. v. Davis, 310 P.3d 824, 829 (Wash. Ct. App. 2013) 13 (quoting Payne v. Saberhagen Holdings, Inc., 190 P.3d 102, 113 (Wash. Ct. App. 2008)). 14 In other words, “a prevailing defendant should not recover more than an amount 15 necessary to compensate him for the added litigative burdens resulting from the 16 plaintiff’s use of [Washington’s] long-arm statute.” Scott Fetzer Co., 786 P.2d at 271. 17 Washington courts have determined that “[i]t may be the case that this amounts to zero.” 18 Payne, 190 P.3d at 113. 19 The court declines to exercise its discretion to award Emcure attorneys’ fees and 20 costs for two reasons. 21 // 22 1 First, “[t]he purpose for which fee-shifting is often utilized,” deterring harassment 2 of foreign defendants, “is not present in the instant case.” Lion Fisheries LLC v. A1
3 Transmission & Marine, Inc., No. C23-0984JCC, 2023 WL 8188674, at *1 (W.D. Wash. 4 Nov. 27, 2023) (refusing to award attorneys’ fees under RCW 4.28.185(5) due to an 5 absence of harassment). (See generally Mot. (making no direct allegations of harassment 6 or bad faith); Reply (same). See also Mot. at 6 (arguing that “HDT’s motives for suing 7 Emcure were unclear”).) 8 Second, Emcure has failed to show that it incurred additional fees as a result of
9 HDT’s pursuit of a claim under Washington’s UTSA. HDT makes this argument (Resp. 10 at 3), but Emcure does not respond to it (see generally Reply). Instead, Emcure argues 11 that “state rules provide grounds for a fee award” in this case. (Id.) That statement may 12 be true, but the state rule is clear: Emcure may only recover fees necessary to 13 compensate it for the “added costs of litigating in Washington.” Payne, 190 P.3d at 113.
14 Emcure seeks over $3 million in fees but fails to identify a single dollar it spent solely as 15 a result of HDT’s pursuit of a claim under the Washington UTSA. (See generally Mot.) 16 Nor could it. As Emcure itself recognizes, HDT brought “parallel” claims (Reply at 3); 17 consequently, the court would have considered the parties’ state and federal claims 18 together. See AgroFresh Inc. v. Essentiv LLC, No. 16-662 (MN), 2020 WL 7024867, at
19 *3 n.7 (D. Del. Nov. 30, 2020) (“Given the overlap between state-adopted versions of the 20 Uniform Trade Secrets Act and the DTSA, courts often analyze parallel state and federal 21 claims of trade secret misappropriation together.”); Traverse Therapy Servs., PLLC v. 22 Sadler-Bridges Wellness Grp., PLLC, No. C23-1239MJP, 2024 WL 381180, at *3 (W.D. 1 Wash. Feb. 1, 2024) (noting that claims under the DTSA and Washington’s UTSA have 2 “substantially similar” elements and overlapping definitions of misappropriation).
3 Emcure concedes that it cannot recover attorneys’ fees under the DTSA. (Mot. at 4 4.) Emcure cannot sidestep the federal law where it fails to show that it incurred any 5 additional fees defending against HDT’s state law claim.2 In sum, the court concludes 6 that Emcure is not entitled to attorneys’ fees and costs under RCW 4.28.185(5) because 7 one of the key purposes for which the statute is often utilized is not present in this case 8 and because Emcure incurred no additional fees as a result of HDT’s pursuit of a claim
9 under the Washington UTSA. 10 IV. CONCLUSION 11 For the foregoing reasons, the court DENIES Emcure’s motion for attorneys’ fees 12 (Dkt. # 199).
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Cite This Page — Counsel Stack
HDT Bio Corp v. Emcure Pharmaceuticals Ltd, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hdt-bio-corp-v-emcure-pharmaceuticals-ltd-wawd-2024.